Xenon Pharmaceuticals (XENE) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Join SI Premium – FREE
Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($1.15), in-line with the analyst estimate of ($1.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanuwave Q2 2026 revenue tops revised guidance range
- Shutterstock CEO Paul Hennessy steps down; CFO named interim chief
- Entrée Resources names Chris Adams as new CEO effective July 17
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
